An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Administration of Two Strengths of Ciprofloxacin for Inhalation Compared With Placebo for Inhalation in the Management of Pseudomonas Aeruginosa in Patients With Non Cystic Fibrosis Bronchiectasis.

Trial Profile

An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Administration of Two Strengths of Ciprofloxacin for Inhalation Compared With Placebo for Inhalation in the Management of Pseudomonas Aeruginosa in Patients With Non Cystic Fibrosis Bronchiectasis.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs Ciprofloxacin (Primary)
  • Indications Bronchiectasis; Pseudomonal infections; Respiratory tract infections
  • Focus Therapeutic Use
  • Acronyms ORBIT-1
  • Most Recent Events

    • 08 Dec 2016 This trial was completed in Germany (end date: 2011-06-06), according to European Clinical Trials Database.
    • 28 Aug 2012 Actual end date (June 2011) added as reported by ClinicalTrials.gov record.
    • 21 Sep 2011 Additional results will be presented at the European Respiratory Society Annual Congress, according to an Aradigm Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top